Opus Genetics, Inc. Increase (Decrease) in Other Operating Assets and Liabilities, Net
Opus Genetics, Inc. (IRD) reported Increase (Decrease) in Other Operating Assets and Liabilities, Net of $5.75 thousand for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-10-29.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet · last filed 2020-10-29
- Opus Genetics, Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2020-09-30 was $2.45K, a 64.25% increase year-over-year.
- Opus Genetics, Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2020-06-30 was $1.81K.
- Opus Genetics, Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2020-03-31 was $1.49K, a 65.88% decline year-over-year.
- Opus Genetics, Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2019-12-31 was $1.49K.
- Opus Genetics, Inc. increase (decrease) in other operating assets and liabilities, net for fiscal 2019 was -$3.72K, a 110.11% decline from fiscal 2018.
- Opus Genetics, Inc. increase (decrease) in other operating assets and liabilities, net for fiscal 2018 was $36.82K.
| Period end | Increase (Decrease) in Other Operating Assets and Liabilities, Net 3 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 6 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 9 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 12 month |
|---|---|---|---|---|
| 2020-09-30 | $2.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $4.26K derived: sum of 2 quarters · filed 2020-10-29 | $5.75K 10-Q · filed 2020-10-29 | $7.24K derived: sum of 4 quarters · filed 2020-10-29 |
| 2020-06-30 | $1.81K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $3.30K 10-Q · filed 2020-08-14 | $4.79K derived: sum of 3 quarters · filed 2020-08-14 | $6.28K derived: sum of 4 quarters · filed 2020-10-29 |
| 2020-03-31 | $1.49K 10-Q · filed 2020-05-07 | $2.98K derived: sum of 2 quarters · filed 2020-05-07 | $4.47K derived: sum of 3 quarters · filed 2020-10-29 | -$6.61K derived: sum of 4 quarters · filed 2020-10-29 |
| 2019-12-31 | $1.49K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $2.98K derived: sum of 2 quarters · filed 2020-10-29 | -$8.10K derived: sum of 3 quarters · filed 2020-10-29 | -$3.72K 10-K · filed 2020-02-21 |
| 2019-09-30 | $1.49K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | -$9.59K derived: sum of 2 quarters · filed 2020-10-29 | -$5.21K 10-Q · filed 2020-10-29 | |
| 2019-06-30 | -$11.08K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | -$6.71K 10-Q · filed 2020-08-14 | ||
| 2019-03-31 | $4.37K 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $36.82K 10-K · filed 2020-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |